Mechanisms involved in drug-induced cholestasis in humans remain poorly understood. Although cyclosporine A (CsA) and tacrolimus (FK506) share similar immunosuppressive properties, only CsA is known to cause dose-dependent cholestasis. Here, we have investigated the mechanisms implicated in early cholestatic effects of CsA using the differentiated human HepaRG cell line. Inhibition of efflux and uptake of taurocholate was evidenced as early as 15 min and 1 h respectively after addition of 10M CsA; it peaked at around 2 h and was reversible. These early effects were associated with generation of oxidative stress and deregulation of cPKC pathway. At higher CsA concentrations (≥50M) alterations of efflux and uptake activities were enhanced and became irreversible, pericanalicular F-actin microfilaments were disorganized and bile canaliculi were constricted. These changes were associated with induction of endoplasmic reticulum stress that preceded generation of oxidative stress. Concentration-dependent changes were observed on total bile acid disposition, which were characterized by an increase and a decrease in culture medium and cells, respectively, after a 24-h treatment with CsA. Accordingly, genes encoding hepatobiliary transporters and bile acid synthesis enzymes were differently deregulated depending on CsA concentration. By contrast, FK506 induced limited effects only at 25-50M and did not alter bile canaliculi. Our data demonstrate involvement of different concentration-dependent mechanisms in CsA-induced cholestasis and point out a critical role of endoplasmic reticulum stress in the occurrence of the major cholestatic features.
ABBREVIATIONS
Adverse drug reactions (ADRs) are usually classified as either dose-dependent and reproducible (intrinsic) or unpredictable (idiosyncratic) occurring only in certain susceptible patients and being not overtly dose-dependent (Park et al., 2005) . Many different classes of marketed drugs and herbals have been reported to cause drug-induced liver injury (DILI) in humans, accounting for more than 50% of cases of acute liver failure in the United States (Lee, 2003) . DILI encompasses a large spectrum of lesions, including apoptosis/necrosis, phospholipidosis, steatosis, and cholestasis. Intra-hepatic cholestasis represents a frequent manifestation of DILI in humans (Lee, 2003) . In many cases, it results from alterations of the hepatobiliary transporter system, in particular the bile salt export pump (BSEP), which is the most physiologically important canalicular bile transporter (Stieger et al., 2007) . Other disturbances, such as altered cell polarity, disruption of cell-to-cell junctions, and cytoskeleton disorganization, can also participate in cholestasis. The mechanisms by which drugs induce cholestasis are diverse and remain poorly understood (Anthérieu et al., 2013) . Intracellular signaling has emerged as a fundamental mechanism to explain the development of different models of cholestasis (Crocenzi et al., 2004) ; thus, the Ca 2+ -dependent PKC isoforms (cPKC) have been demonstrated to be involved in estradiol 17ß-D-glucuronide (E17G)-and tertbutylhydroperoxide-induced cholestasis Pérez et al., 2006) . A role for oxidative stress as a primary causal agent and/or an aggravating factor has been evidenced in extrahepatic and intrahepatic cholestasis (Anthérieu et al., 2013; Pérez et al., 2006; Roma and Pozzi, 2008) . Cyclosporine A (CsA) is well recognized as a dose-dependent cholestatic inducing agent. It has been shown to alter bile secretion in in vitro (Princen et al., 1991) and short-term in vivo studies (Mizuta et al., 1999) . CsA also acts as a competitive inhibitor of BSEP, MRP2, and MDR1 and caused disorganization of pericanalicular F-actin cytoskeleton (Román and Coleman, 1994) . CsA disturbs the endoplasmic reticulum (ER)-Golgi transport by altering vesicle-mediated transport (Sarró et al., 2012) . By contrast, tacrolimus (FK506), another immunosuppressant that possesses similar immunosuppressive properties as CsA (Tocci et al., 1989) , has usually no effect even at supra-therapeutic concentrations in humans. The reasons why the liver is so differently sensitive to the two immunosuppressant agents remain unclear.
In the present study, we have investigated early effects of CsA and FK506 in the metabolically competent human HepaRG cells. In addition to phases I and II metabolizing enzymes (Aninat et al., 2006) , these cells exhibit functional sinusoidal and canalicular transporters and are now largely used for studying both acute and chronic effects of xenobiotics in human liver (Anthérieu et al., 2012; Guguen-Guillouzo and Guillouzo, 2010) . Our data show that unlike FK506, CsA induced early cholestatic effects, involving different dose-dependent mechanisms in HepaRG cells.
MATERIALS AND METHODS
Chemicals. Cyclosporine A (CsA), methylthiazoletetrazolium (MTT), N-acetyl-cysteine (NAC), 4-phenyl butyric acid (PBA), 1-(5-isoquinolinylsulfonyl)-2-methyl-piperazine (H7), and 5(6)-carboxy-2 ,7 -dichlorofluorescein diacetate (CDF) were purchased from Sigma (St. Quentin Fallavier, France). Tacrolimus fetal bovine serum, 100 IU/ml penicillin, 100 mg/ml streptomycin, 5 mg/ml insulin, 2mM glutamine, and 50mM hydrocortisone hemisuccinate. After 2 weeks, HepaRG cells were shifted to the same medium supplemented with 2% dimethyl sulfoxide (DMSO) for further 2 weeks in order to obtain confluent differentiated cultures with maximum functional activities. At this time, these cultures contained hepatocyte-like and progenitors/primitive biliary-like cells (Cerec et al., 2007) .
Cell viability. Cytotoxicity was evaluated by the MTT colorimetric assay. Briefly, cells were seeded in 24-well plates and treated with various concentrations of CsA and FK506. After medium removal, 500 l serum-free media containing MTT (0.5 mg/ml) were added to each well and incubated for 2 h at 37
• C. The water-insoluble formazan was dissolved in 500 l DMSO and absorbance was measured at 550 nm (Aninat et al., 2006) .
Measurement of reactive oxygen species.
Reactive oxygen species (ROS) generation was determined by the H2-DCFDA assay. Cells were incubated for 2 h at 37
• C with 2M H2-DCFDA; then they were washed with cold phosphate buffered saline (PBS) and scraped in phosphate buffer (10mM, pH 7.4)/methanol (vol/vol) supplemented with Triton X-100 (0.1%). Fluorescence intensity of cell extracts was determined by spectrofluorimetry using excitation/emission wavelengths of 498/520 nm (Anthérieu et al., 2013) . (Anthérieu et al., 2013) .
Real
F-actin distribution. After cell exposure to CsA or FK506, cells were washed twice with warm PBS, fixed with 4% paraformaldehyde for 20 min at 4
• C and permeabilized with 0.3% Triton in PBS for 30 min. F-actin and nuclei were labeled simultaneously using a phalloidin fluoprobe diluted at 1/100 and 5 ng/ml Hoechst dye, respectively, for 20 min. Imaging was done using the Cellomics ArrayScan VTI HCS Reader (Thermo Scientific) (Anthérieu et al., 2013) .
Time-lapse imaging. Phase-contrast images were taken each minute after exposure of HepaRG cells to both immunosuppressant agents, using time-lapse phase-contrast videomicroscopy (Zeiss Axiovert 200M and AxioCam MRm). The inverted microscope was equipped with a thermostatic chamber (temperature and CO 2 ) to maintain the cells under physiological conditions. Images were captured with a 20× objective and the mosaic tool of the microscope which enabled the automated acquisition of multi-image mosaics at the defined positions.
Measurement of endogenous bile acid content. After treatment of
HepaRG cells with CsA for 4 and 24 h both cells and media were collected, lyophilized and stored at −80 • C. Ten l of water was added to 100 mg dried samples, homogenized using a Polytron homogenizer for 30 s, and clarified by centrifugation at 20,000 × g for 20 min. The supernatant was collected and extracted using a solid phase extraction cartridge (SPE). High pressure liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) was used to measure bile acid (BA) content in the samples. The chromatographic separation of BAs was carried out on a Zorbax eclipse XDB-C18 (Agilent Technology, Garches, France) fitted on an Agilent 1100 HPLC system (Massy, France). The column was thermostated at 35
• C. The mobile phases consisted of (A) (ammonium acetate 15 mmol/l, pH 5.3) and (B) (methanol) at 65:35 (vol/vol). BAs were eluted by increasing B in A from 65 to 95 (vol/vol) for 30 min. Separation was achieved at a flow rate varying between 0.3 and 0.5 ml/min for 30 min. Mass spectra were obtained using an API 2000 Q-Trap (AB-Sciex, Concord, Ontario, Canada) equipped with a TurboIon electrospray interface set in the negative mode (needle voltage-4500 V) with nitrogen as the nebulizer set at 40 (arbitrary pressure unit given by the equipment provider). Curtain and heater pressures were set at 20 and 40, respectively (arbitrary units), and the ion source temperature was set at 400
• C. Declustering and entrance potentials were set at −60 V and −10 V, respectively. The MS/MS detection was operated at unit/unit resolution. The acquisition dwell time for each transition monitored was 70 ms. Data were acquired by the Analyst software (version 1.4.2, AB-Sciex) in the Multiple Reaction Monitoring mode (Humbert et al., 2012) .
Western blot analysis of MAPK phosphorylation. Activation of p38-MAPK was assessed by evaluating its phosphorylation status in cell lysates by Western blotting. Briefly, HepaRG cells were incubated with medium alone or with CsA, FK506, and CsA plus inhibitors for 15 or 120 min, washed with cold phosphate-buffered saline, and finally resuspended in cell lysis buffer and a protease inhibitor cocktail. Aliquots containing an equivalent total protein content, as determined by the Bradford procedure with bovine serum albumin as the standard, were subjected to sodium dodecyl sulfate/12% polyacrylamide gel electrophoresis, electrotransferred to Immobilon-P membranes, and probed overnight with a rabbit antiphosphorylated p38 (Cell Signaling Technology, Beverly, MA). After using a mouse anti-rabbit IgG secondary antibody (1:5000, 1 h; ThermoFisher Scientific, Waltham, MA), a chemiluminescence reagent, and Hyperfilm ECL, phosphorylated and total MAPK bands were quantified by densitometry with Fusion-Capt software (Vilber Lourmat, Fusion FX7, France) .
Statistical analysis. The student's t-test was applied to compare data between treated and corresponding control cultures. Data were considered as significantly different when *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001.
RESULTS

Cytotoxicity Effects of CsA and FK506
Cytotoxicity of both CsA and FK506 was evaluated in HepaRG cells using the MTT test. CsA did not cause any significant cytotoxicity after 24 h at concentrations up to 100M. By contrast, FK506 was highly toxic at 100M causing 94% cell death (p Ͻ 0.001; Fig. 1A ). Based on these data, non-toxic concentrations from 0 to 50M of both drugs were selected for further studies.
Induction of ROS and ER Stress by CsA
Because deregulation of the cellular redox status is a potent mechanism in DILI, generation of oxidative and ER stress was analyzed after exposure to the two immunosuppressant agents. Significant production of ROS was observed in HepaRG cells , or co-treated with 50M CsA + 15mM NAC or 5mM PBA for 2 h. H2O2 at 25mM was used as a positive control. ROS generation was detected by the DCFDA specific substrate. (C and D) Cells were treated with CsA or FK506 or co-treated with 50M CsA + (15mM NAC or 5mM PBA) for 6 h, then mRNA levels of ROS markers (HO-1, MnSOD, and Nrf2) and ER stress markers (CHOP, GRP78, ATF4, and ATF6) were estimated by RT-qPCR. Data represent the means ± SD of three independent experiments. All results are expressed relative to the levels found in untreated cells, arbitrarily set at 1 or 100% *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001 compared with non-treated cells,
starting at 10M (twofold; p Ͻ 0.05) after 2 h (Fig. 1B) . ROS formation occurred within the first 15 min after CsA addition (data not shown), peaked after 2 h (3.8-fold; p Ͻ 0.01) and was totally prevented by co-incubation with 15mM of the antioxidant NAC. Only a slight ROS production was obtained with 50M FK506 after 2 h (Fig. 1B) . Moreover, transcript levels of three ROS markers (Nrf2, HO-1, and MnSOD) were also measured and found to be significantly up-regulated as early as 6 h after CsA exposure (Fig.  1C) . Overexpression of Nrf2 was lower with FK506 and occurring only at 50M. Moreover, four ER stress-related genes (ATF4, ATF6, GRP78, and CHOP) were strongly up-regulated after 6 h treatment with 50M CsA, whereas only a slight increase of CHOP transcripts was observed with 50M FK506 (Fig. 1D) . Co-treatment with PBA, an ER stress inhibitor, prevented induction of ER stress-related genes. Interestingly, co-treatment with PBA also reduced ROS generation and induction of ROS-related genes, suggesting a link between ER stress and ROS triggered by CsA. However, NAC reduced induction of ROS markers without affecting ER stressrelated genes.
In addition, PBA failed to lower ROS induced by H 2 O 2 and the cholestatic drug chlorpromazine where no ER stress was observed (Supplementary data 1), indicating that PBA was able to decrease ROS by reducing ER stress, as is the case with high CsA concentrations. any inhibition observed at 10M (Fig. 2A) . To better characterize CsA effects on TA efflux, a time-dependent study was carried out between 0 and 6 h after treatment with 10 and 50M. Efflux inhibition was evidenced as early as 15 min after CsA addition, whereas its maximum occurred after 2 h. At low CsA concentrations, inhibition was partially restored after 6 h. At higher CsA concentrations inhibition of TA efflux was totally maintained after 6 h (Fig. 2B ).
Effects of CsA and FK506 on Influx and Efflux Transporters
To estimate MRP2 activity, HepaRG cells were exposed to both drugs for 2 h followed by incubation with CDF, an MRP2-specific substrate. CsA inhibited canalicular excretion of CDF at both 10 and 50M concentrations; no effect was observed with FK506 even at 50M (Fig. 2C) .
The effect of the two immunosuppressant agents on Na + -dependent BA uptake was estimated through measurement of intracellular accumulation of [ 3 H]-TA after a 30-min incubation.
CsA-induced inhibition of NTCP activity started after 30 min with 50M and 1 h with low doses (≤10M); it reached a maximum after 2 h and started to be restored after 4 h exposure at low doses, whereas inhibition of [ 3 H]-TA uptake was maintained with 50M (Fig. 2D) 
Role of cPKC, ER, and Oxidative Stress in CsA-Induced Effects
It has been demonstrated that cPKC partly accounts for acute cholestasis caused by E17G (Fig. 3A) . However, this inhibition was totally restored by cotreatment with either PBA or NAC. Interestingly at low CsA concentrations, co-treatment with PBA has no counteraction effect, favoring a role of ER stress only at high CsA concentrations. By contrast, NAC was totally effective at low and high CsA concentrations indicating a role of ROS in CsA-induced cholestasis whatever the drug concentration (Fig. 3B) . The downstream effector of cPKC, p38, was previously shown to be involved in E17G-cPKC-dependent induced cholestasis (Fig. 3B) . Accordingly, Western blotting analysis of phospho (p)-p38 showed that CsA increased the amount of p-p38 in a time-dependent manner with increment becoming apparent as soon as 5 min after CsA administration. Co-treatment with either the cPKC inhibitor Go¨6976 or NAC selectively prevented p-p38 increase, indicating that p38 activation was dependent on cPKC induction and ROS generation by CsA (Figs. 3C and 3D ).
Effects of CsA on BA Disposition
In order to determine whether CsA altered disposition of endogenous BAs, total BA content was quantitated in both media and cells after 4 and 24 h exposure to 10 and 50M CsA using HPLC-MS/MS. Although no changes were evidenced after 4 h, a concentration-dependent increase of BA content in the medium and decrease in cells was observed after 24 h of CsA treatment. The sum of total BAs content (media + cells) appeared to be nearly unchanged between 4 and 24 h (Fig. 4) .
Induction of Cytoskeletal F-Actin Disruption and Bile Canaliculi Constriction by High CsA Concentrations
F-actin cytoskeleton is one of the primary targets of oxidative stress. To determine whether CsA and FK506 disrupted cytoskeletal F-actin distribution, HepaRG cells were exposed to both drugs at different time points and then cytoskeletal F-actin was visualized by phalloidin fluoprobe labeling. Untreated cells showed typical pericanalicular distribution of F-actin and large bile canaliculi with an open lumen (Fig. 5A ). At 10M CsA did not affect actin distribution in the pericanalicular area ( Fig. 5B ) whereas at 50M it disrupted its distribution, lowered its labeling intensity, and caused constriction of bile canaliculi after 2-h exposure (Fig. 5D ). These effects were confirmed by phasecontrast time-lapse imaging. Retraction and disappearance of bile canaliculi were observed in 50M CsA-treated cells (Fig.  5G' ). FK506 did not alter cytoskeletal F-actin distribution nor bile canaliculi structures (Figs. 5C and 5F').
Effects of CsA and FK506 on Expression of Genes Related to Cholestasis
Many genes involved in BA transport, synthesis, and metabolism are deregulated in cholestasis. A set of target genes was analyzed by RT-qPCR after 24-h treatment with various concentrations of CsA and FK506. (Pedersen et al., 2013) . CsA also induced a concentration-dependent decrease in NTCP activity measured by Na + -dependent TA uptake starting after 1 h at low doses (10M) and even after 30 min at high doses, thereby indicating that inhibition of uptake occurred shortly after efflux inhibition. CsA has been previously shown to decrease uptake of BA in the liver (Murray et al., 2011) but our observation represented the first direct demonstration that inhibition of TA uptake was reversible with low CsA concentrations. Early effects on efflux and influx of BA by CsA were associated with generation of an oxidative stress and involved deregulation of the cPKC/p38 pathway. A role for oxidative stress as a primary causal agent in induction of drug-induced cholestasis has been reported (Anthérieu et al., 2013; Pérez et al., 2006) . Several arguments support the involvement of an oxidative stress in CsA-induced cholestasis, especially ROS generation, and prevention of CsA-induced BSEP activity inhibition and decrease in phospho-p38 protein in the presence of NAC. Compelling evidence that ROS-mediated cholestasis can involve activation of intracellular signaling cascades via cPKC has been provided ( Pérez et al., 2006) , and its association with endocytic internalization of BA transporters, such as Mrp2 and Bsep, has been reported Pérez et al., 2006) . The downstream effector p38-MAPK has been shown to be differently activated by cPKC isoforms in E17G-induced cholestasis . If cPKC was recently reported to play a major role in CsA toxicity (Sarró et al., 2012) , to our knowledge our work is the first to link the sequential activation of cPKC-p38 as a mechanism of CsA-induced cholestasis. Amplified and irreversible effects of high CsA concentrations on efflux and influx of TA were associated with ROS production and overexpression of ROS markers, Nrf2, HO-1, and MnSOD, disruption of cytoskeletal pericanalicular F-actin, and constriction of bile canaliculi structures. These effects appeared to be related primarily to induction of an ER stress. Indeed, four major ER stress markers, ATF4, ATF6, GRP78, and CHOP, were overexpressed and addition of NAC did not prevent their induction, contrary to PBA, a specific inhibitor of ER stress (Basseri et al., 2009; Carlisle et al., 2014) . Obviously, these data support a hierarchical relationship between ER stress and ROS in CsA-induced effects. Contrary to CsA both H 2 O 2 (this study) and chlorpromazine (Anthérieu et al., 2013) were able to induce ROS without induction of an ER stress. Moreover, PBA failed to reduce ROS generation by these two molecules (Supplementary data 1) , indicating that it cannot reduce ROS unless an ER stress is induced. These data suggest that ER stress might precede an oxidative stress in HepaRG cells treated with high CsA concentrations. This is supported by a recent study on renal proximal tubule cells, which identified ER stress as an early effector of CsA cytotoxicity, leading to ROS generation (Sarró et al., 2012) .
The mechanism of CsA-induced ER stress remains poorly studied. A recent proteomic analysis of CsA-treated HepG2 cells has evidenced deregulation of some proteins related to an ER stress without concluding whether it was a primary event in CsA action (Van Summeren et al., 2011) . ER stress has been linked to perturbation of cyclophilins A and B distribution in a CsAtreated human kidney cell line (Lamoureux et al., 2011) . The relevance between CsA-induced ER and oxidative stress could be related to deregulation of ER-mitochondria Ca 2+ -signaling bridge. Indeed, ER stress often stimulates a cascade of cellular and molecular events that lead to changes in ER Ca 2+ concentration resulting in activation of Ca 2+ -dependent PKC and ROS production (Orrenius et al., 2003) . Several arguments support a role of Ca 2+ in ER and oxidative stress-mediated effects during
CsA-induced acute cholestasis, mostly the effectiveness of the Ca 2+ -chelator BAPTA/AM in reducing CsA cholestatic effects at low concentrations. However, the lack of a Ca 2+ chelation effect at high CsA concentrations could be explained by the severity and irreversibility of the effects induced by CsA at high doses. Our data clearly showed that CsA induced ER stress and ROS in HepaRG cells at concentrations which were not cytotoxic whereas FK506 was highly toxic in the absence of ER stress and ROS formation. Accordingly, CsA, but not FK506, was recently reported to induce ER stress in endothelial cells (Bouvier et al., 2009) . There is currently no report showing induction of ER stress by FK506 in vivo.
Although no obvious change was found in the medium/cells ratio of BAs after a 4-h treatment with 10 or 50M CsA a concentration-dependent increase in this ratio was observed after 24 h, indicating a cellular (intracellular + bile canaliculi) decrease and not, as it could be expected, an accumulation of BAs. This decrease was not related to a diminution in the content in total BA between 4 and 24 h. These data with CsA as well as those previously obtained with chlorpromazine (Anthérieu et al., 2013) clearly showed that cholestatic features rapidly appeared in HepaRG cells after drug addition; inhibition of BSEP occurred within 1 h and only shortly preceded that of NTCP whereas bile canaliculi constriction was observed within 4 h, giving support to a rapid adaptation of the cells to cholestatic drug effects. The rapid inhibition of the uptake transporter NTCP, bile canaliculi constriction associated with BA discharge, and increased basolateral excretion likely explained the increased medium/cells ratio of BAs after 24 h of CsA treatment. Accordingly, troglitazone, another potent inhibitor of BSEP, failed to induce intracellular accumulation of BAs in human and rat sandwich-cultured hepatocytes, and this result was attributed to compensatory mechanisms which help to maintain BA homeostasis and low intracellular BA concentrations (Marion et al., 2012) .
Various cholestasis-related genes were also found to be differently deregulated depending on CsA concentration after a 24-h treatment. At low concentrations the major changes involved overexpression of PXR, CAR, CYP3A4, NTCP, and BCRP. Although CsA is recognized as a direct inhibitor of CYP3A4 activity (Amundsen et al., 2012) , previous studies have reported induction of CYP3A4 transcripts by CsA through activation of PXR in human primary hepatocytes (Wallace et al., 2010) . Because BCRP is known to be regulated by Nrf2, its overexpression could be related to early Nrf2 activation by CsA (Singh et al., 2010) .
Conversely, overexpression of the basolateral MRP3 and MRP4 transporters, and down-regulation of NTCP, CYP27A1, and CYP7A1, the initiator of the BAs biosynthetic pathway, with high CsA concentrations could represent an adaptive defense response aimed at reducing BA accumulation and concomitant toxicity (Zollner and Trauner, 2008) .
Compared with CsA, FK506 induced some cholestatic effects only at 50M, a concentration close to its toxic concentration. Only, NTCP, MRP3, and MRP4 were deregulated with 25M FK506 and to a much lower extent than with 25M CsA. Moreover, cytoskeletal pericanalicular F-actin and bile canaliculi were not altered. Because FK506 is used at 10-to 100-fold lower doses than CsA, the absence of hepatotoxic and cholestatic effects at concentrations up to 25M fully agreed with its safety reported in clinics (Mihatsch et al., 1998) . Noteworthy, if similar in vitro observations as with CsA were recently reported with chlorpromazine the effects of this idiosyncratic cholestatic drug were, however, observed only at 50M, a concentration close to its maximum nontoxic concentration (Anthérieu et al., 2013) . Accordingly, considering the Cmax values measured in patients, i.e., 1.15, 0.1-0.2, and 0.05M for CsA, chlorpromazine, and FK506, respectively, cholestatic concentrations are expected to be reached only in patients treated with CsA. These findings suggest that it might be possible to discriminate between dose-dependent and idiosyncratic cholestatic drugs using the HepaRG cell model.
In summary, we demonstrate that reversibility of CsAinduced cholestatic effects is concentration-dependent using HepaRG cells and that ER and oxidative stress are major causal events and involved Ca 2+ -dependent signaling pathways.
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